Ciltacabtagene autoleucel

Carvykti 0,15 - 1,0 x 10E8 cellen, dispersie voor infusie

Dispersie voor infusieNetherlandsAuthorisedAuthorised 25 May 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

CarvyktiEuropean UnionAuthorised

Carvykti®Brazil · Janssen-Cilag Farmacêutica LtdaSame brand
CarvyktiCanada · 100000000 CELLS / BAG · Suspension · Janssen INCSame brand
CARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSIONSpain · 3.2 X 10⁶ -1.0 X 10⁸ CELULAS · dispersion para perfusion · Janssen-Cilag International N.VSame brand
CarvyktiEuropean Union · Janssen-Cilag International NVSame brand
CarvyktiCroatiaSame brand
CarvyktiItaly · Dispersione per infusione · Janssen-Cilag International N.V.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ciltacabtagene autoleucel

Carvykti 0,15 - 1,0 x 10E8 cellen, dispersie voor infusie

Dispersie voor infusieNetherlandsAuthorisedAuthorised 25 May 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

CarvyktiEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

CarvyktiUnited States · 0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion · For Injection · Janssen Biotech, Inc.

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ciltacabtagene autoleucel
Dosage form: Dispersie voor infusie
Route: Intraveneus gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 25 May 2022
Registration: EU/1/22/1648
Marketing authorisation holder: Janssen-Cilag International NV
ATC code: L01XL05
Group: Antineoplastic and immunomodulating agents
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/005095
EU number: EU/1/22/1648